ORIC Latest Headlines

Stifel Nicolaus Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)

at www.tipranks.com (Thu, 29-Oct 10:16 PM)

Oric Pharmaceuticals (ORIC) Receives a Buy from Wedbush

at www.tipranks.com (Tue, 27-Oct 9:36 AM)

Boris Peaker Reiterates Buy on ORIC, Sees Compelling Risk-Reward with Unchanged $25 Price Target

at www.tipranks.com (Tue, 27-Oct 8:45 AM)

Analyst Reiterates Buy on ORIC Pharmaceuticals, Citing Best-in-Class Potential for Enozertinib and Maintaining $27 Price Target

at www.tipranks.com (Tue, 27-Oct 7:27 AM)

ORIC spotlights 84% confirmed ORR for enozertinib in 1L EGFR atypical NSCLC, with Phase 3 Redwood-1 planned for 1H 2027

Market Chameleon (Mon, 26-Oct 11:07 AM)

Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Oric Pharmaceuticals (ORIC)

at www.tipranks.com (Mon, 26-Oct 5:50 AM)

ORIC sets Oct. 23 call to spotlight enozertinib Phase 1b data for first-line NSCLC with EGFR atypical mutations

Market Chameleon (Tue, 20-Oct 11:08 AM)